Moreover, treatment costs for breast cancer can vary based on both the disease characteristics such as hormone receptor and human epidermal growth factor receptor 2 (HER2) status [9, 10] and patient-specific factors such as complications and comorbidities [11]. This evidence concerns the gene ERBB2 and breast carcinoma.